TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from PolyPeptide Group AG ( (CH:PPGN) ).
PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized contract developer and manufacturer (CDMO) focusing on peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves the pharmaceutical and biotech sectors, contributing to the health of millions globally. It operates six GMP-certified production facilities worldwide and is listed on the SIX Swiss Exchange.
Average Trading Volume: 65,555
Current Market Cap: CHF642.8M
See more insights into PPGN stock on TipRanks’ Stock Analysis page.